Get started
Author

Sarah Rachel Barton

Observed names: S Barton, S. Barton, Sarah Barton, Sarah R. Barton
OpenAlex ID: A5110265166
Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer
2012 · S Barton, L Zabaglo, et al. · British Journal of Cancer · 67
PDF
miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial
2016 · Khurum Khan, David Cunningham, et al. · Oncotarget · 44
PDF
The role of ipsilateral breast radiotherapy in management of occult primary breast cancer presenting as axillary lymphadenopathy
2011 · Sarah R. Barton, Ian E. Smith, et al. · European Journal of Cancer · 44
Are We Ready To Stratify Treatment for Diffuse Large B-Cell Lymphoma Using Molecular Hallmarks?
2012 · Sarah Barton, Eliza A. Hawkes, et al. · The Oncologist · 43
Predictive Molecular Markers of Response to Epidermal Growth Factor Receptor(EGFR) Family-Targeted Therapies
2010 · Sarah Barton, Naureen Starling, et al. · Current Cancer Drug Targets · 30
Recent Developments in Treatment Stratification for Metastatic Breast Cancer
2011 · Sarah Barton, Charles Swanton · Drugs · 18
Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R‐ GEM ‐P) is an effective regimen in relapsed diffuse large B‐cell lymphoma
2014 · Sarah Barton, Eliza A. Hawkes, et al. · European Journal Of Haematology · 12
GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma
2013 · Eliza A. Hawkes, Sarah Barton, et al. · Annals of Hematology · 8
R-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma: results of the UK NRCI phase II randomised LEGEND trial
2019 · Andrea Kühnl, Clare Peckitt, et al. · Annals of Hematology · 7
The influence of industry sponsorship on the reporting of subgroup analyses within phase III randomised controlled trials in gastrointestinal oncology
2015 · Sarah Barton, Clare Peckitt, et al. · European Journal of Cancer · 6
Abstract 3589: Validation of the role of circulating tumor DNA (ctDNA) in tracking mechanisms of resistance to anti-EGFR monoclonal antibodies (AE-mABs): preliminary results of the PROSPECT-C prospective trial
2015 · Khurum Khan, George Vlachogianis, et al. · Cancer Research · 1
ANTI-CD30 Antibody Drug Conjugate Therapy in Hodgkin Lymphoma and CD30+ Lymphoma
2013 · I. Chau, S. Barton · Annals of Oncology · 1
Targeting triple-negative sporadic and hereditary BRCA-related metastatic breast cancer
2011 · Sarah Barton, Nicholas C. Turner · CRC Press eBooks · 1
Rituximab, gemcitabine, cisplatin, and methylprednisolone (R-GEM-P) in treatment of relapsed diffuse large B-cell lymphoma (DLBCL).
2013 · Sarah Rachel Barton, Eliza Anne Hawkes, et al. · Journal of Clinical Oncology
Reporting of subgroup analyses (SGA) in phase III randomized trials in gastrointestinal (GI) cancer.
2013 · Sarah Rachel Barton, Ian Chau, et al. · Journal of Clinical Oncology
Targeting triple-negative sporadic and hereditary BRCA-related metastatic breast cancer
2011 · Sarah Barton, Nicholas C. Turner · Informa Healthcare eBooks
Works count: 16
Citation count: 282
H-index: 8
I10-index: 7
Year
Topic
Type